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Abstract
Focal therapy is an emerging treatment modality for localised prostate cancer that aims to reduce the morbidity seen with radical therapy, while maintaining
cancer control. Focal therapy treatment strategies minimise damage to non-cancerous tissue, with priority given to the sparing of key structures such as the
neurovascular bundles, external sphincter, bladder neck and rectum. There are a number of ablative technologies that can deliver energy to destroy cancer cells
as part of a focal therapy strategy. The most widely investigated are cryotherapy and high-intensity focussed ultrasound. Existing radical therapies, such as
brachytherapy and external beam radiotherapy, also have the potential to be applied in a focal manner. The functional outcomes of focal therapy from several
phase I and II trials have been encouraging, with low rates of urinary incontinence and erectile dysfunction. Robust medium- and long-term cancer control
outcomes are currently lacking. Controversies in focal therapy remain, notably treatment paradigms based on the index lesion hypothesis, appropriate patient
selection for focal therapy and how the efﬁcacy of focal therapy should be assessed. This review articles discusses the current status of focal therapy, highlighting
controversies and emerging strategies that can inﬂuence treatment outcomes for the future.
 2013 The Royal College of Radiologists. Published by Elsevier Ltd.
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This review summarises the rationale for focal therapy, its
current status and future perspectives.Rationale for Focal Therapy
Current options for men with localised prostate cancer
include active surveillance and radical therapy. The ideal
treatment would provide oncological cure with few side-
effects. Although radical therapy offers treatment with
curative intent there can be a high rate of associated func-
tional complications, with erectile dysfunction seen in
24e90%, urinary incontinence in 2e72% and rectal toxicity
in 2e15% [1e4]. These complications detrimentally affect
quality of life [2,5].
In the era of prostate-speciﬁc antigen (PSA) screening,
there has been an increase in the detection of prostate cancer
[6]. Men are being diagnosed at an earlier stage and the
proportion of men with low-risk disease is increasing [7,8].
The debate over population-based PSA screening continues,
withdifferingﬁndings fromtheEuropeanRandomisedStudyOpen access under CC BY license.
V. Kasivisvanathan et al. / Clinical Oncology 25 (2013) 461e473462of Screening for Prostate Cancer (ERSPC) and the Prostate,
Lung, Colorectal and Ovarian (PLCO) randomised controlled
trials leading to the recent US Preventive Services Task Force
recommendation against population-based PSA screening
[9,10]. However, the high rates of contamination of the
control arms in ERSPC RotterdamSection (31%) and the PCLO
trial (40e52%) [10,11] and the emerging patterns of PSA
screening in other countries [12] show that physicians and
men favour PSA screening. These men may be unnecessarily
exposed to the harms of radical treatment. The Prostate
cancer Intervention Versus Observation Trial (PIVOT) study,
which randomised men diagnosed during the early PSA
screening era betweenwatchful waiting and radical surgery,
suggests that men with low-risk localised prostate cancer
have no beneﬁt from treatment with regards to prostate
cancer-speciﬁc mortality [13]. Other minimally invasive op-
tions for these men should be actively considered.
Active surveillance takes advantage of the slow pro-
gression of low-risk disease, allowing about two-thirds of
men who enter an active surveillance programme to avoid
radical treatment and its side-effects [14,15]. The mortality
rates for patients on active surveillance is low at 0e1%, but
due to the inherent errors of the diagnostic transrectal bi-
opsy, it is unclear which cancers are intermediate- and
high-risk at baseline and there are concerns that delaying
radical therapymay lead to disease progression andmissing
the opportunity for curative treatment. Furthermore, the
anxiety and burden of repeated hospital visits, PSA tests and
biopsies to the individual and healthcare systems should
not be underestimated [16e19]. This may explain why less
than 8% of eligible patients in the USA and 39% of those
eligible in the UK opt for active surveillance [7,20].
Focal therapy has been proposed as an alternative
minimally invasive technique that aims to destroy the
tumour itself or the region containing the tumour in order
to preserve surrounding non-cancerous tissue. The goal is to
maintain disease control at acceptable levels, while pre-
serving erectile, urinary and rectal function by minimising
damage to the neurovascular bundles, external sphincter,
bladder neck and rectum. This approach has gained
increasing attention over the last 5 years, with encouraging
evidence accumulating on functional outcomes and short-
term oncological outcomes [21e25].Fig 1. Diagrammatic representation of focal therapy strategies. The red
lesion represents clinically signiﬁcant prostate cancer and the green
lesion represents clinically insigniﬁcant prostate cancer. The yellow cir-
cles represent the neurovascular bundles and the blue rectangle repre-
sents theablationzone. Lesion-targeted therapy is representedby (a)e(c).
In (a), unifocal ablationpreserves the contralateral neurovascular bundle.
In (b), although clinically signiﬁcant cancer is present bilaterally, one
neurovascular bundle is still spared. In (c), clinically insigniﬁcant cancer
near thesecondneurovascularbundle isnot treated.Only the index lesion
is treated, allowing preservation of one neurovascular bundle. In (d), an
example of region-targeted therapy, hemi-ablation, is presented.Focal Therapy Treatment Strategies
A number of focal therapy strategies have commonly been
used (Figure 1). In general, they differ by whether they
attempt to ablate speciﬁc cancer foci (lesion-targeted therapy)
orwhole regions containing cancer (region-targeted therapy).
Focal therapy is classically considered for men with a
single discrete tumour or several foci in one half of the
prostate. A recent systematic review showed that 13e67% of
patients have unifocal or unilateral disease [26]. A further
strategy, which extends the proportion of men eligible for
focal therapy treatment, is the index lesion ablation strat-
egy. This involves treating only the largest and highest-
grade tumour (the index lesion), while sparing small foci
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may not contribute to disease progression over a 10e20
year period.
In the presence of multifocal disease, the index lesion has
been shown to determine the clinical progression of disease
[26e29]. Molecular genetics studies suggest that a single
tumour focus is responsible for metastasis and disease
progression and that this focus is the index lesion [30,31].
The critical tumour volume that correlates to a ‘clinically
signiﬁcant’ lesion that will probably contribute to disease
progression, has often been proposed as 0.5 ml [32,33].
Region-targeted therapy treats a larger area of the pros-
tate in the region of the tumour with the rationale that
treating multiple tumour foci may give a greater certainty of
cure while still preserving vital structures [34]. Hemi-
ablation of the half of the prostate containing the tumour
is the most commonly reported focal therapy strategy.
Subtotal prostate ablation of volumes greater than half the
prostate, for example hockey stick ablation, has also been
shown [35]. However, the more extensive the treatment, the
more likely the functional outcomes will approach those of
radical therapy. Overall, it is estimated that between one-
half and two-thirds of men with localised prostate cancer
may be amenable to some form of focal therapy [36,37].Patient Selection for Focal Therapy
Most focal therapy trials have included men with low-
risk (low volume, Gleason grade 6) disease for whom
active surveillance has shown a very low 10e15 year mor-
tality [14]. However, for those groups that include
intermediate-risk (Gleason grade 3 þ 4) disease in active
surveillance protocols [38] or those that consider focal
therapy a potential alternative to radical therapy [39], pa-
tients with intermediate- and high-risk (Gleason grade
4 þ 3 or greater) disease would be suitable and have been
included [24,40], although there is much disagreement on
this [41]. A limitation of including intermediate- and high-
risk men is their higher rate of micro-metastases and dis-
ease progression, even after radical therapy [42,43], which
means including them in a focal therapy trial may increase
the risk of early treatment failure, making it difﬁcult to fully
interpret treatment efﬁcacy.
Retreatment of tumours with focal therapy is possible,
although the greater the amount of tissue ablated on the
ﬁrst occasion, the more limited the second treatment can be
[24]. After focal therapy, men are still eligible for radical
therapy, although it may be technically more challenging
[44]. Focal salvage therapy after external beam radiotherapy
has also been shown [45,46]. This approach is based on the
observation that the main site of recurrence is usually at the
site of the original index lesion [47e49].Localisation of Disease
For focal therapy to be successful, key requirements are
the ability to accurately and reliably identify all clinicallysigniﬁcant tumours in the prostate, guide the focal ablation
energy to the tumour and assess the treated area to deter-
mine treatment efﬁcacy. There is no single modality that
meets these requirements, although currently a combina-
tion of biopsy and imaging techniques is best practice.
For the selection of men for focal therapy, a 5 mm
transperineal template prostate mapping (TPM) biopsy is
the current recommended standard [50]. It can provide
three-dimensional coordinates of speciﬁc cancer foci. TPM
has an approximate 95% sensitivity and negative predictive
value in detecting and ruling-out clinically signiﬁcant can-
cer [51,52]. In patients who have had unilateral cancer
identiﬁed on transrectal ultrasound (TRUS) biopsy, 61%
were found to have bilateral cancer after reclassiﬁcation by
TPM, and 23% of patients had Gleason scores upgraded to 7
or higher [53]. The consequences of the random and sys-
tematic error of TRUS biopsy is that clinically signiﬁcant
cancers may be missed, men may be inappropriately
selected for focal therapy and when assessing treatment
efﬁcacy, differentiating between ablation failure or sam-
pling error may be difﬁcult. TPM is not without its own
burden, however. It is time-consuming, requires a general
anaesthetic and is associated with a urinary retention rate
of 2e11% [54e57].
Elastography, tissue characterisation imaging modalities
and contrast-enhanced ultrasound have shown variable
degrees of success in the identiﬁcation of clinically signiﬁ-
cant cancer [58e62], although the imaging modality that
has attracted themost interest ismulti-parametricmagnetic
resonance imaging (MP-MRI), which uses functional para-
meters (dynamic contrast-enhanced, diffusion-weighted or
magnetic resonance spectroscopy) and anatomical para-
meters (T2-weighted imaging) and has shown a sensitivity,
speciﬁcity and negative predictive value of 86, 94 and 95%,
respectively, for the identiﬁcation of tumours greater than
0.5 ml, when compared against radical prostatectomy
specimens [63,64]. Evidence suggests that Apparent diffu-
sion coefﬁcient (ADC) values in diffusion-weighted imaging
and metabolite ratios in spectroscopy may correlate to the
aggressiveness of the cancer [65e67].
The interpretation of prostate MRI does, however,
require experienced uro-radiologists and attempts at
standardising MRI conduct and reporting have been made
[68,69], with validation of reporting standards [70]. TPM
still remains necessary before selecting suitable candidates
for focal therapy, although we await the results of the
PROMIS trial (NCT01292291), which may shed more light
on the validity of MP-MRI in the detection of clinically sig-
niﬁcant prostate cancer.Guiding Focal Therapy
Although the three-dimensional location of the tumour
for focal ablation can be attained from TPM and MP-MRI,
further challenges include the application of the ablative
energy to that speciﬁc location, given that the prostate is
viewed most often by real-time TRUS. Tumour location on
MP-MRI images may be reviewed before TRUS-guided focal
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real-time TRUS images with software platforms (software
registration), which allow the MRI images or their contours
of prostate and tumours to be overlaid on the TRUS viewing
screen. As an alternative to using TRUS, MRI can be used to
guide procedures and for real-timemonitoring of treatment
intensity [71]. However, MRI-compatible equipment is
expensive, can be cumbersome to use and may require
more time to gain expertise. Despite this, signiﬁcant prog-
ress is being made with the technology [72,73].Ablative Technologies for Focal Therapy
The technologies with the most functional and onco-
logical outcome data are high-intensity focussed ultrasound
(HIFU) and cryotherapy. There have been no randomised
control trials comparing the ablative technologies with each
other or with standard of care, although a relatively large
focal therapy series of 106 patients using a number of
ablative technologies has been reported revealing a major
complication rate of less than 2% with 100% continence
rates postoperatively [25]. It is clear that prospective
outcome data are required before these technologies are
used routinely in clinical practice, but the key data currently
available shall be presented.
Focal High-intensity Focussed Ultrasound
HIFU is applied by inserting an ultrasound probe into the
rectum, which allows both the prostate to be visualised and
energy to be delivered to the prostate. HIFU uses energy with
more than5Wofpowerappliedper cm2at frequencieswithin
the 2.25e4MHz range, focussing this energy on to an intense
point inwhich the density can be as high as 1500W/cm2. The
ultrasound wave is absorbed by tissue and converted to heat,
typically above 80 C, which results in coagulative necrosis. In
addition, alternating cycles of compression and rarefaction
leadto inertial cavitation,whichresults incellnecrosis.HIFU is
best used inmenwith prostates that have an anteroposterior
diameter of less than 40 mm and without prostatic calciﬁca-
tion, although the use of transurethral resection of prostate
and cytoreduction can allow larger glands to be treated.
Outcomes of key studies of focal HIFU are given in Table 1
[24,25,35,74,75]. Continence rates of 90e100%, potency rates
of 89e95% and 6e12 month biopsy-free recurrence rates of
77e92% have been reported after treatment, although not all
cancer recurrences were clinically signiﬁcant.
Focal Cryotherapy
Cryotherapy causes cellular destruction by freezing tissue
tobelow30 C. This is achievedbyargon-based cryoprobes,
which can be inserted transperineally into prostate tumour
typically under TRUS guidance. Freezing is achieved by the
JouleeThompson effect, which results in ice-ball formation
at the needle tip, which can be manipulated in size. The size
of the ice-ball can be crudely monitored with TRUS during
the procedure. The ice crystals cause cell death by disruptingcell membranes, causing cell lysis and disrupting the
microvasculature leading to cellular ischaemia. Urethral
warming devices and thermocouples for systematic tem-
perature monitoring can be used to minimise collateral
damage, although urethralwarming could theoretically lead
to undertreatment of anteroseptal tumours. Outcomes of
key studies of focal cryotherapy are given in Table 2
[25,40,76e79]. Continence rates of 96e100%, potency rates
of 71e90% and biopsy-free recurrence rates of 60e94% have
been reported. Of note, most of the described recurrences
occurred in the untreated area of the prostate.
Focal Photodynamic Therapy
Focal photodynamic therapy (PDT) involves the adminis-
tration of a photosensitising agent, which when activated by
light within the prostate, causes cellular destruction. The
photosensitising agent is commonly administered intrave-
nously and is activated by light from optical ﬁbres inserted,
most commonly, transperineally into the desired area of the
prostate under TRUS guidance. Activation results in the pro-
duction of reactive oxidative species, such as the singlet ox-
ygen, which cause direct cellular injury and vascular damage
and lead to cell necrosis andapoptosis.AsPDTdependson the
presence oxygen it may not be effective in hypoxic prostate
tumours. Reliable treatment planning is difﬁcult to achieve
given the requirement of appropriate levels of oxygen, pho-
tosensitiser and light in the tumour. Only a few studies
showing feasibility of the technique have been published
(Table 3) [25,80e82], although a randomised controlled trial
of active surveillance versus hemi- or subtotal PDT therapy
has almost completed recruitment (NCT01310894).
Focal Photothermal Ablation
Focal photothermal ablation involves the thermal
destruction of cells by application of laser from optical ﬁ-
bres inserted transperineally into the tumour, most
commonly under MRI guidance. Increasingly, the 980 nm
diode laser is being used with procedures carried out under
MRI guidance, requiring fully compatible MRI equipment.
After several minutes of treatment, a 1 cm near-spherical
ablation zone is produced and although it can be
extended by manipulation of the ﬁbre position, this tech-
nology is ideal for smaller discrete tumours. MRI allows
real-time temperature monitoring to ensure that the tem-
peratures required to ablate tumour cells are reached and to
reduce the risk of collateral damage. Key reports of photo-
thermal ablation are described in Table 4 and show the
feasibility of the technique [83e87]. Further data on func-
tional and oncological outcomes are awaited and phase I/II
trials (NCT01094665) are in progress.
Focal Therapy Using Radiation
Established treatments such as brachytherapy using high
dose rate iridium-192 or permanent low dose rate seeds,
commonly of iodine-125 and palladium-103, can also be
applied in a focal manner. Seeds can be placed via small
Table 1
Outcomes of key studies in focal high-intensity focussed ultrasound
Reference No.
patients
Follow-up
(years)
Gleason
score
PSA
(ng/ml)
Disease
localisation
Ablation strategy Continence Potency Adverse events Oncological outcomes
Muto et al.,
2008 [35]
29 2.6 5e10 5.4 MRI and
TRUS
biopsy
Posterior hockey
stick ablation
29/29
(100%)
NR 1 year biopsy:
13/17 (77%) no cancer
2 years BDFS (ASTRO criteria):
83% in low-risk patients
54% in intermediate-risk patients
0% in high-risk patients
Ahmed et al.,
2011 [74]
20 1 4 þ 3 7.3 MP-MRI
and TPM
Hemi-ablation 18/20
(90%)
19/20
(95%)
Urethral stricture
1/20 (5%)
6 months biopsy:
17/19 (89%) no cancer
19/19 (100%) no signiﬁcant cancer
El Fegoun et al.,
2011 [75]
12 10 3 þ 4 7.3 TRUS
biopsy
Hemi-ablation 12/12
(100%)
NR Retention 1/12 (8%)
UTI 2/12 (17%)
1 year biopsy:
11/12 (92%) no cancer
5 years:
Recurrence-free survival e 90%
10 years:
Recurrence-free survival e 38%
Cancer-speciﬁc survival 10/10
(100%)
Ahmed et al.,
2012 [24]
41 1 4 þ 3 6.6 MP-MRI
and TPM
Lesion-targeted
or Region-
targeted
38/38
(100%)
31/35
(89%)
Retention 1/41 (2%)
UTI 7/41 (17%)
Urethral stricture 1/41
(2%) Diarrhoea and urine
extravasation 1/41 (2%)
6 months biopsy:
30/39 (77%) no cancer
36/39 (92%) no signiﬁcant cancer
Barret et al.,
2012 [25]
21 0.75 6 6 TPM Hemi-ablation 21/21
(100%)
IIEF-5
decrease
from 20
to 14
Retention 5/21 (24%) NR
PSA, mean/median pre-procedural prostate-speciﬁc antigen; TRUS, transrectal ultrasound guided; NR, not reported; BDFS, biochemical disease-free survival; ASTRO criteria, three
successive increases in PSA; MP-MRI, multi-parametric magnetic resonance imaging; TPM, transperineal template mapping biopsy; UTI, irinary tract infection; IIEF-5¼ International
Index of Erectile Function.
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Table 2
Outcomes of key studies in focal cryotherapy
Reference No.
patients
Follow-up
(years)
Gleason
score
PSA
(ng/ml)
Disease
localisation
Ablation
strategy
Continence Potency Adverse events Oncological outcomes
Bahn et al.,
2006 [76]
31 5.8 7 4.9 TRUS
biopsy
Hemi-ablation 31/31
(100%)
24/27
(89%)
During follow-up:
24/25 (96%) no cancer on biopsy
1/1 recurrence in untreated lobe
BDFS (ASTRO)e 26/28 (94%)
Lambert et al.,
2007 [77]
25 2.3 7 6 TRUS
biopsy
Hemi-ablation 25/25
(100%)
17/25
(71%)
Retention 1/25
(4%)
During follow-up:
22/25 (88%) no cancer on biopsy
2/3 recurrences in untreated lobe
BDFS (Phoenix) e22/25 (88%)
Ellis et al.,
2007 [78]
60 1.25 7 7.2 TRUS
biopsy
Hemi-ablation 53/55
(96%)
24/34
(71%)
During follow-up:
21/35 (60%) no cancer on biopsy
13/14 recurrences in untreated lobe
BDFS (ASTRO) e48/60 (80%)
Onik et al.,
2008 [79]
48 4.5 NR 7.8 TPM Lesion-targeted 48/48
(100%)
36/40
(90%)
Sloughed tissue 1/4
(2%) requiring TURP
During follow-up:
43/48 (90%) no cancer on biopsy
5/5 recurrences in untreated area
BDFS (ASTRO) e 45/48 (94%)
Bahn et al.,
2012 [40]
73 3.7 7 5.4 TRUS
biopsy
Hemi-ablation 70/70
(100%)
86% During follow-up:
36/48 (75%) no cancer on biopsy
11/12 recurrences in untreated lobe
Barret et al.,
2012 [25]
50 0.75 6 6.2 TPM Hemi-ablation 50/50
(100%)
IIEF-5
decrease
from 19
to 14
Retention 4/50 (8%)
Gross haematuria 1 0
(2%) requiring irriga ion
and blood transfusi .
1/50 (2%) stricture. /50
(2%) perineal absce with
rectal ﬁstula requir g
excision and tempo ry
colostomy.
NR
PSA, mean/median pre-procedural prostate-speciﬁc antigen; TRUS, transrectal ultrasound guided; BDFS, biochemical disease-free surv al; ASTRO criteria, three successive increases
in PSA; Phoenix criteria, PSA nadirþ 2 ng/dl; TPM, transperineal templatemapping biopsy; TURP, transurethral resection of prostate; N , not reported; IIEF-5¼ International Index of
Erectile Function.
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Table 3
Key studies of focal photodynamic therapy
Reference No.
patients
Gleason
score
Photosensitiser Ablation
strategy
Light
delivery
Continence Potency Adverse events Oncological outcomes
Windahl
et al.,
1990 [80]
2 NR Haematoporphyrin
derivative (n ¼ 1)
Photofrin (n ¼ 1)
Post-TURP
remnant
TU NR NR At 3 months:
2/2 no cancer on control
biopsies
Reduction in mean PSA
from 8 to 1.35 ng/ml
Zaak et al.,
2003 [81]
6 5e8 5-ALA Variable RP
(n ¼ 1)
TU
(n ¼ 3)
TP
(n ¼ 2)
6/6
(100%)
NR For one patient who had
radical prostatectomy:
Necrosis at site of ﬁbre
insertion
At 6 weeks:
Reduction of PSA by
20e70%
Moore et al.,
2006 [82]
6 3 þ 3 Temoporﬁn Hemi-
ablation
TP NR 2/3
(67%)
Retreatment
(n ¼ 4) due to
residual cancer
Sepsis (n ¼ 1)
Voiding
symptoms
requiring
recatheterisation
(n ¼ 2)
At 2 months:
0/6 no cancer on biopsy
PSA reduction after 8/10
treatments
Barret et al.,
2012 [25]
23 6 Padeliporﬁn Region-
targeted
23/23
(100%)
IIEF-5
decrease
from 23
to 13
NR
TURP, transurethral resection of prostate ; TU, transurethral; RP, during radical prostatectomy; TP, transperineal; NR, not reported; IIEF-5,
International Index of Erectile Function; PSA, prostate-speciﬁc antigen.
Table 4
Key reports of focal photothermal ablation
Reference No.
patients
Laser Ablation strategy No.
ﬁbres
Real-time
imaging
Adverse events Outcomes
Amin et al.,
1993 [83]
1 805 nm
Diomed
diode laser
Lesion-targeted 3 US and CT Mild dysuria 10 days:
Biopsy e necrosis in ablation
zone
Linder et al.,
2009 [84]
12 830 nm
Indigo
diode laser
Lesion-targeted 1e2 3D-US
CEUS
Retention (n ¼ 2)
Perineal discomfort
(n ¼ 3)
Mild haematuria
(n ¼ 2)
Haematospermia
(n ¼ 2)
Fatigue (n ¼ 1)
6 month biopsy:
6/12 (50%) no cancer
4/6 recurrences in
ablation zone
6 month functional outcome:
Potency e 100% of men
potent pre-procedure
retained potency
Continence e no signiﬁcant
worsening of IPSS score
Linder et al.,
2010 [85]
4 980 nm
Visualise
diode laser
Lesion-targeted 2e3 CEUS Good correlation between
ablation volume on MRI
and ablation volume on
H&E stained pathology images
Raz et al.,
2010 [86]
2 980 nm
Visualise
diode laser
Lesion-targeted 2 3D 1.5 T MRI
CEUS
Immediate repeat treatment
with new ﬁbre position due
to residual vascularised target
tissue
Linder et al.,
2011 [87]
2 980 nm
Visualise
diode laser
Lesion-targeted NR 3D robotic
1.5 T MRI
No signiﬁcant change in IIEF-5
or IPSS scores after treatment
US, ultrasound; CT, computed tomography; MRI, magnetic resonance imaging; CEUS, contrast-enhanced ultrasound; 3D, three-dimensional;
H&E, haematoxylin and eosin; NR, not reported; IIEF-5, International Index of Erectile Function; IPSS, International Prostate Symptom Score.
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Fig 2. Magnetic resonance imaging (MRI) appearances before and
after focal high-intensity focussed ultrasound treatment to the
prostate. A T2-weighted prostate MRI image of a manwith presenting
prostate-speciﬁc antigen of 7.7 ng/ml is given in (a). A scanner with a
1.5 Tesla magnet and a pelvic phased array coil was used to capture
V. Kasivisvanathan et al. / Clinical Oncology 25 (2013) 461e473468catheters inserted transperineally into the prostate using
TRUS guidance. With pretreatment planning it is possible to
apply a higher radiation dose to the tumour with a lower
dose to the surrounding non-cancerous tissue. Barret et al.
[25] carried out focal brachytherapy in 12 patients who
maintained continence post-procedurally, although inter-
national index of erectile function scores decreased from 21
at baseline to 14 after the procedure. Larger focal brachy-
therapy trials are now underway (NCT01354951).
One group has also applied peripheral zone-targeted and
urethral-sparing low dose rate brachytherapy, observing
encouraging adverse effect proﬁles and 5 year biochemical-
free survival rates in low-risk patients [88,89]. Focal
brachytherapy has also shown good use in the salvage
setting after failed whole-gland irradiation, where repeat
full doses of radiation would not be feasible [90,91].
A recent consensus meeting gave recommendations on
patient selection and technical considerations for focal low
dose rate brachytherapy [92]. Of note is the emphasis on
pretreatment planning, the use of iodine-125 seeds linked
with a low activity, consideration of organs at risk, including
the shape of the prostatic urethra, and post-implant
dosimetry at 24 h or 4 weeks. It was suggested that
further modelling is required for prescription dose recom-
mendations and ideal margin size is currently uncertain.
High dose rate brachytherapy to a partial volume of the
prostate has been used as a boost after external beam
radiotherapy [93] and several ongoing phase I and II trials
are investigating its use as a boost to the dominant intra-
prostatic lesion (NCT00807820, NCT01605097). External
beam radiotherapy itself can be used in a focal manner by
targeting radiation delivery to speciﬁc areas of the prostate.
The CyberKnife, a device that can be used to deliver ste-
reotactic radiation precisely, has been used to target the
peripheral zone [94] and dominant lesions [95].
Other Ablative Energies
Radiofrequency ablation, applied via electrodes inserted
transperineally, can induce thermal damage to the prostate
andhas been shown tobe a feasible focal therapy technology
for prostate cancer [96,97] and is under further investigation
(NCT01423006). Irreversible electroporation is a promising
non-thermal ablation technology that has been applied in a
number of other solid organ cancers, showing quick, precise
and predictable tissue destruction in high-risk anatomical
areas [98,99]. A clinical trial of irreversible electroporation in
focal therapyofprostate cancer is underway (NCT01726894).
Future prospective ablative technologies include the use of
gold andmagnetic nanoparticles that canbedirectly injected
into tumours, producing heat upon activation by electro-
magnetic stimulation [100].images. An anterior prostate tumour is indicated by the red circle.
Transperineal template prostate biopsies conﬁrmed high volume
Gleason 3 þ 3 disease. The patient underwent focal high-intensity
focussed ultrasound treatment of the tumour. Six months after
treatment, the patient underwent repeat MRI and the T2-weighted
MRI image obtained is given in (b). The ablation cavity can be seen
with no evidence of residual cancer. Prostate-speciﬁc antigen at this
time was 1.1 ng/ml.Evaluating Focal Therapy Treatment
Contrast-enhanced ultrasound and MRI can be used for
real-time feedback of tissue destruction with most focal
therapy technologies [101,102]. Contrast-enhanced MRI canalso be used at an early stage, for example within the ﬁrst
week after focal therapy for veriﬁcation of treatment effect.
Subsequent follow-up for the assessment of oncological
control is more challenging. PSA values are difﬁcult to
interpret because a variable amount of prostate tissue re-
mains after focal therapy. Further factors inﬂuencing post-
procedural PSA include the proportion of pre-procedural
PSA that was due to the tumour, the efﬁcacy of the abla-
tion therapy and the progression of benign prostate hy-
perplasia. Thus, a speciﬁc threshold nadir for PSA to deﬁne
biochemical recurrence is unlikely to be derived. Deﬁnitions
that are currently used to deﬁne failure in whole gland ra-
diation therapy (ASTRO [three consecutive rises in PSA from
nadir], Phoenix deﬁnition [nadir þ 2 ng/dl]) have been used
V. Kasivisvanathan et al. / Clinical Oncology 25 (2013) 461e473 469in focal therapy, although they have not yet been validated.
Certainly, a standardised biopsy scheme to conﬁrm the
presence or absence of disease after focal therapy is
essential and evidence from whole gland treatment using
focal ablation technology supports the role of imaging such
as MP-MRI to detect recurrences [103e105]. In summary, a
combination of biochemical, histological and imaging re-
sults can be used to evaluate the oncological control ach-
ieved by focal therapy (Figure 2).
There is a wide range of follow-up protocols in focal
therapy trials. In general, PSA is checked 3 monthly for the
ﬁrst year, then 6 monthly [35,74,76,77,106]. A scheduled
prostate biopsy is carried out at 6e12 months or with PSA
progression.Discussion
The aim of focal therapy is to obtain the trifecta status of
oncological cure, potency and continence. Treatment stra-
tegies can be lesion-targeted or region-targeted withTable 5
Notable ongoing trials in focal therapy
Trial number
identiﬁer
Focal ablation
modality
Phase Description Inten
no.
patie
NCT01194648 HIFU Phase II Multi-centre
Single-arm
272
NCT00988130 HIFU Phase II Single-centre
Single-arm
Index lesion
ablation
26
NCT01310894 PDT Phase III Multi-centre
RCT Active
surveillance
versus focal
therapy
400
NCT01094665 Photothermal Phase I/II Single-centre
Single-arm
60
NCT01354951 LDR-
brachytherapy
Phase II Single-centre
Single-arm
80
NCT00807820 HDR-
brachytherapy
Phase I Single-centre
Single-arm
Selective boost
to DIL
56
NCT01423006 RFA Phase I Single-centre
Single-arm
7
NCT01726894 IRE Phase I Single-centre
Single-arm
20
HIFU, high-intensity focussed ultrasound; PDT, photodynamic therap
ablation; IRE, irreversible electroporation; RCT, randomised controlle
template mapping prostate biopsy; TRUS, transrectal ultrasound; PSA,emphasis on preserving neurovascular bundles, bladder
neck, external sphincter and rectum. A number of ablative
technologies are available, the best studied of which include
HIFU and cryotherapy. Although it is clear that more data,
particularly on medium- and long-term cancer control, are
required, encouraging functional outcomes have now been
reported.
Controversies of focal therapy remain. Primarily, current
trials do not present medium- and long-term oncological
outcome data or comparisons with existing standards of
care. There is also no consensus on whether oncological
control should be deemed the absence of any cancer or the
absence of clinically signiﬁcant cancer and whether this
should be limited to the treated area or include the un-
treated prostate. The selection of men suitable for focal
therapy is another point of contention. Most of those who
consider it an alternative to active surveillance would
consider low-risk Gleason 6 as suitable, whereas those
considering it an alternative to radical therapy would
consider higher-risk disease suitable. The index lesion hy-
pothesis has also been challenged, with some weakded
nts
Selection criteria Key outcomes
T1eT3a
Gleason  4 þ 3
PSA < 15 ng/ml
Proportion of men free
of any cancer and free of
clinically signiﬁcant prostate
cancer at 36 months on TPM
T3b
Gleason  8
PSA  20 ng/ml
Side-effects and quality of life
Absence of cancer in treated
area at 12 months by TRUS
biopsy
T2c
Gleason  3 þ 3
PSA  10 mg/ml
Rate of absence of deﬁnite
cancer at 24 months
Rate of failure with observed
progression of disease from
low risk to higher risk
T1eT2a
PSA < 15 ng/ml
Absence of cancer at 4 months
on TRUS biopsy
T1c-T2a
Gleason 7 in two
cores or less
PSA < 10 ng/ml
Toxicity at 6 months to 2 years
Absence of cancer at 12 and 24
months on biopsy
T2ae2b, Gleason 2e6,
PSA 10e20 ng/ml or
T3ae3b, Gleason 2e6,
PSA  20 ng/ml or
T2ae3b, Gleason 7e10,
PSA  20 ng/ml
Rate of  grade 3 genitourinary
or gastrointestinal toxicity at
12 months
T1c
Gleason  6
PSA < 10 ng/ml
Absence of cancer at 6 months
on biopsy
T1eT2c
Gleason  7
PSA  15 ng/ml
Adverse events at 12 months
y; LDR, low dose rate; HDR, high dose rate; RFA, radiofrequency
d trial; DIL, dominant intra-prostatic lesion; TPM, transperineal
prostate-speciﬁc antigen.
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from tumours other than the index lesion [107]. Certainly,
any untreated lesions must be meticulously monitored in
these men.
Much progress has been made in focal therapy over the
last 10 years and there is still much to be made. The results
of several prospective trials are eagerly awaited, one that
will present 3 year cancer control data after HIFU (NCT01
194648) and another that will present the results of the
index lesion ablation strategy (NCT00988130) (Table 5). If
reliable and consistent local control of cancer can be proven,
the next step would be randomised controlled trials
comparing active surveillance or radical therapy with focal
therapy. For these trials to be successful it is important that
they are pragmatic and have an adaptive approach to
design, for example, the cohort multiple randomised con-
trol trial design [108].
Trials need not limit focal therapy to one speciﬁc ablative
technology, but can include any that have proven efﬁcacy in
local cancer control. Indeed, different ablative energies may
be advantageous in different circumstances. Outcomes of
mortality and metastatic progression would require a large
number of men with a 10e15 year follow-up and so other
outcomes need to also be considered, such as functional
outcomes and side-effects using validated patient ques-
tionnaires, the rate of additional systemic therapy and cost-
effectiveness. In contrast to the adoption of laparoscopic and
robotic radical prostatectomy, with focal therapy we have
the opportunity to evaluate the results of a new technique in
well-designed prospective clinical trials in a timely manner.Conﬂicts of Interest
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